Abstract Independent studies have shown that in node negative breast cancer patients less than 71 years, the proliferation marker mitotic activity index (MAI) is the strongest, most well reproducible prognosticator and chemotherapy success predictor. The MAI overshadows the prognostic value of tubule formation, nuclear atypia and thereby grade. An often used crude mitotic impression is much less prognostic than the MAI; strict adherence to the MAI protocol is therefore important. The prognostic value of the MAI is age dependent: although patients with a MAI C 10 always have a poor prognosis irrespective of age, a low MAI (\10) loses its favourable prognostic association in women [70 years. PPH3 counts are prognostically stronger than the MAI, and markers such as Cyclin-B and E2FR are promising, but must be validated. Compared with commercial prognostic gene expression signatures, the MAI is at least as strong prognostically, has far fewer false positive results and as such should be included as an independent feature in any node negative breast cancer pathology report.
Introduction
The prognosis of patients with lymph node-negative breast cancer is relatively good (20-30% die from recurrent disease). Their improvement of survival with adjuvant systemic therapy is less substantial than that for lymph node-positive patients; the typical 15-year survival difference for treated and untreated patients is approximately 35% (relative) and 10% (absolute). Both the benefits and disadvantages of this 10% absolute improvement in survival must be considered when deliberating adjuvant systemic therapy [1, 2] and prognostic/predictive features are important in these decisions.
Often, a combination of features is used in the decision making process for adjuvant systemic therapy, where tumour diameter, oestrogen receptor, grade, vessel invasion and also age play a major role [3, 4] . A simplified version of this is the St. Gallen guideline, which identifies 85% or more of all node-negative patients as high risk, but as only *25% of these patients die from metastatic disease without adjuvant treatment, the remaining 60% are over-treated. On a worldwide basis, a more sensitive and specific prognosticator could therefore prevent enormous unnecessary suffering.
Proliferation markers such as the mitotic activity index (MAI) and Thymidine Labelling Index (TLI) are prognostically stronger than classical prognosticators and predictors, as shown in many prospective and retrospective (also multicentre) analyses [5] [6] [7] . Moreover, while studies evaluating the role of individual genes regulating these processes have increased our knowledge of the complex process of proliferation, the functional end result is dividing cells. This is microscopically visible as mitotic figures which have remained the most important prognostic factor so far [8] . Moreover, the MAI is widely available, easy to use, inexpensive, and highly reproducible [9, 10] . A large, multicentre prospective [9] long follow-up study showed that lymph node negative patients with high proliferation (MAI C 10) have the same poor outcome as women with 1-3 positive lymph nodes (Fig. 1) . Moreover, in two independent studies, adjuvant chemotherapy was significantly beneficial to patients with rapidly proliferating tumours but not to patients with slowly proliferating tumours [11, 12] (Table 1) .
Although proof of a crucial prognostic and predictive role of proliferation is thus very strong, two small studies did not confirm this [13, 14] . Smaller studies inevitably carry the risk for selection bias, but other error sources should also be considered. In order to explain these discrepancies we have analyzed possible error sources which will be summarized in this article, together with potentially powerful immuno-histochemical alternatives for the MAI. Validation of a prognostic test in independent multicentre test-set studies is mandatory for a diagnostic or therapeutic clinical laboratory test [15, 16] .
The MAI assessment must be strictly protocolized; quality control
One objection against mitotic activity assessment is that it is subjective and not well reproducible, although this contradicts its strong prognostic value. Moreover, in the largest multicentre reproducibility study on the MAI, comprising more than 2,000 breast cancers from 35 hospitals, correlation coefficients between the original laboratory and duplicate (blind) assessments by four independent observers were 0.90-0.98 with little or no bias for most laboratories [17] . Importantly, a strict MAI assessment protocol was used in studies showing strong prognostic value of the MAI. The following measures (partly adapted from references [5, 9, 10, 17] ) must be taken.
Field of vision specification
For comparability of different studies, the area in which the counts are made should be exactly defined and standardized. We have consistently used counts in 10 microscopic fields of vision with a field diameter of 450 lm, which at 4009 magnification result in a total area of 1.59 mm 2 . Moreover, the area of the fields of vision were carefully selected in the highest proliferative invasive area in the periphery of the tumour [9, 17] . In view of the enormous diameter variation of different objective/ocular combinations, expression of the mitotic rate ''per high power field'' without further specification is almost useless ( Table 2 ).
Use adequate samples
Intra-tumour fluctuations of the number of mitoses (heterogeneity) can occur. Therefore, taking just a small fragment or one section per tumour is inadequate; multiple sections of the periphery (growing zone) of the tumour should be analyzed. Use lightly stained 4-5 lm (thin) sections, disregarding poor quality or thick sections. Ignore carcinoma in situ (CIS) and micro-invasive cancer \2 mm diameter, as the surface of the latter in general is \10 fields of vision. Count mitoses in the periphery of the tumour only, disregarding the centre. In the periphery, ignore necrotic or inflamed areas, and those close to the epidermis of the overlying skin (if present). In the tumour periphery, select (at low magnification) the area with the subjectively highest mitotic activity. Demarcate this area, called the Measurement area, which should be minimally 2 9 2 and maximally 5 9 5 mm.
Do not use random or maximized mitosis counts
Select the first field of vision as follows. ''Helicopter scan'' the section with low magnification to find the area within the measurement area with subjectively the highest number of mitoses. Then, zoom in by changing to the 409 objective and count all unambiguous mitotic figures. Once the first field of vision has been selected using the abovementioned criteria, count mitoses in neighbouring fields of vision only; do not maximize the mitosis counts by searching mitoses in non-neighbouring fields of vision (Fig. 2) . The MAI is defined as the total number of unambiguous mitotic figures in 10 neighbouring fields of vision with a total area of 1.56 mm 2 .
The following protocol deviations can lead to wrong MAI results: a. Skipping a neighbouring field of vision that does not contain mitoses. This is only allowed where the field of vision does not contain cancer cells. b. Use of non-representative (small) sections. c. Random counts in the section. d. Inaccurate selection and demarcation of the measurement area. e. Within the measurement area, non-neighbouring fields of vision are selected to attempt to maximize the number of mitoses, resulting in too high or -low MAI values.
Quality control and assurance
The following quality control procedure was applied for the MAI in the prospective Multicenter Morphometric Mammary Carcinoma Project (MMMCP) [9, 17] , as follows:
1. It was checked whether the measurement area had been selected correctly. 2. All cases were measured twice. 3. When one of the assessments was \10, and the other C10, a third evaluation was done with all persons, using a discussion microscope. Each object which was a possible mitosis was discussed and that result used. It was found that discrepancies MAI \ 7 versus [14 were very rare; in daily routine practice, a reasonable and practical Quality Assurance is to recount all cases with 7 B MAI B 14. Table 3 summarizes the different steps for the correct assessment of MAI. The influence of fixation delay on the mitotic activity
The time between excision of the tumour (and hence termination of the circulation) and fixation of the tissue in the pathology laboratory is usually not standardized and therefore widely variable. Some believe that mitoses diminish with delayed fixation. The hypothesis is that mitoses have just enough energy to finalize their course; due to the lack of oxygen no new cells are driven from G0 into G1, and cells in the G1-, S-and G2 phase do not have enough energy to move on to the mitotic phase, resulting in a decrease in the number of mitoses. In the absence of strict standardization and variation of fixation delay, the effect of fixation delay on proliferation parameters such as mitotic activity and S-phase cells is not standardized and therefore would make the MAI unreliable [18, 19] . However, later studies show that the total number of mitotic figures and also the percentage of S-phase cells remain unchanged with fixation delay [20] . It is certainly more difficult to identify mitotic figures after fixation delay which nonetheless should be avoided whenever possible [21] (Fig. 3) .
A quick-scan impression is much less prognostic than accurate MAI assessments
All possible error sources mentioned could in principle be easily controlled or have been falsified. What, then, is the reason for the lack of prognostic value of the MAI in some studies? Selection bias is certainly a possibility: two of the studies without prognostic value for the MAI are small, and do not mention an age limit (see below). Another possible cause is inaccurate mitosis counts. This is psychologically well understandable in a busy daily pathology practice. Grade is widely used for prognostic purposes in breast cancer [22] . Of the three constituents of tumour grade, MAI, Tubule Formation (TF) and Nuclear Atypia (NA), the latter two assessments are fast, requiring B30 s. The World Health Organization [23] defines a strict mitotic count and categorization protocol, in which the number of mitoses is categorized as 0-5 = 1, 6-10 = 2, and [10 = 3. Accurate MAI assessment is more time consuming than TF and NA determination. In practice, the relatively time-consuming 2-3 min procedure for determining MAI is often replaced by a faster procedure, whereby a subjective mitotic impression (MIMP) is obtained by quickly scanning the specimen tissue. The MIMP, like the WHO-MAI, is categorized as 1, 2, or 3 and combined with TA and NA to obtain a histological tumour grade. The results of the two procedures may seem to be very similar, but demonstrating that they are prognostically different required a labourintensive study with many patients. Therefore, the prognostic and therapeutic consequences of MIMP have long (j = 0.41), including 85% for category 1, 26% for category 2, and 52% for category 3. The WHO-MAI was a much stronger prognosticator than the MIMP, and the 10-year survival rates of the same categories (e.g. MAI and MIMP category both 2) differed greatly. When grade was assessed by combining WHO-MAI or MIMP with the same values for tubular formation and NA, grades disagreed in 18% of the cases and its prognostic value diminished (Fig. 4) . It was concluded that deviation from the formal WHO-MAI assessment guidelines in breast cancer often results in erroneous prognosis estimations with therapeutic consequences and may explain why the prognostic value of proliferative activity in breast cancer is not always confirmed [24] . The fact that grade was less prognostic than the MAI, indicates that TF and/or NA dilute rather than strengthen the prognostic value of the MAI.
The prognostic value of the MAI is age dependent
Another important prognostic factor which is often not considered in prognostic studies is the influence of age. This is surprising, since hormonal conditions dramatically change with age and oestrogens are known to stimulate tumour growth. To answer the question, whether the prognostic value of proliferation and especially the MAI in node-negative patients is influenced by age, we investigated the prognostic value of proliferation in 1004 T 1-3 N 0 M 0 invasive breast cancers in different age groups (n = 516, \55 years; n = 322, 55-70 years; n = 166, [70 years) without systemic adjuvant therapy and long follow-up (median: 108 months). It was found that the MAI decreases with age and the prognostic value of MAI varied by age group. For patients \55 years, hazard ratios (HR) for MAI C 10 v \ 10 for distant metastasis-free and overall cancer-related survival were 3.1 and 4.4, respectively (P \ 0.0001 for both), but only 1.9 and 1.9 (P = 0.004 and 0.006) for patients 55-70; while in patients over 70 years, MAI was not significant (P = 0.11) ( The prognostic value of the MAI in special subgroups of node negative patients
The question remains whether the MAI is prognostic in special subgroups of node negative patients that do not usually receive adjuvant systemic chemotherapy = AST, such as those with very small tumours (\1 cm diameter), or tumours between 1 and 3 cm with grades 1 + 2 only. Again, the MMMCP material of 853 operable node-negative invasive breast cancers in women under 71 years without previous or concurrent malignancies and long follow-up, was used. During the enrolment period, the breast cancer treatment general policy in The Netherlands did not include AST for patients with node-negative breast cancer, allowing study of the true biological nature of the cancers in the patient subgroups involved. In all the tumours together (N = 853), in grade 3 (n = 269), in tumours \1 cm all grades (n = 84), 1-2 cm, grades 1 + 2 (n = 300), and 2-3 cm, grades 1 + 2 (n = 124), the MAI is prognostically superior. Other features (grade, oestrogen receptor = OR, diameter, age) did Fig. 4 The MAI assessed by a formalized protocol is a much stronger prognosticator than a quick-scan mitotic impression (MIMP still recommended a three-layered grading system consisting of mitotic counts, tubular formation and NA (each in three different categories). As we described before the prognostic value of proliferation is age dependent. Moreover, unpublished data from our laboratory have shown that the MAI is also prognostic in patients with limited metastatic load in the axillary lymph nodes, but not if many lymph nodes are positive (typically [3) . It is therefore of the utmost importance in prognostic breast cancer studies, to carefully define the age group and nodal status of the patients, as was done in a large prospective study on 1,003 patients with operable node negative breast cancer. In that study it was found that TF and NA had no additional prognostic value to the MAI in patients \71 years of age [25] . Moreover, the prognostic value of the MAI was stronger than grade, indicating that adding information of TF and/or NA weakens the prognostic value one can extract from a breast cancer section, by using the MAI alone [32] .
Comparison of the MAI with other mitosis count procedures
Certain breast cancers are very cellular (like medullary type invasive cancer), whereas others (such as classical Indian filing type lobular invasive cancers) have a low cellularity. It has been advocated that correction for the percentage epithelium versus stroma in cancers, could make proliferation stronger prognostically. Moreover, others have used the mitotic rate, defined as the total number of mitoses per 100, 200 or 1,000 cells. Although such corrections are intuitively attractive, they are time consuming which may negatively influence the determination accuracy.
In a comparative analysis of four different methods to assess mitotic activity, it was investigated whether the prognostic value of mitotic activity could be improved by a random sampling procedure or correction for percentage of epithelium present [33, 34] . For this purpose, the prognostic value of four methods used to assess mitotic activity in invasive breast cancer was compared in 4-microns-thick hematoxylin-eosin (H&E)-stained sections of 186 primary invasive breast cancer patients. These were the MAI, the random MAI (rMAI), the Mitosis per volume (M/V) index, and the random M/V index (rM/V Index). The rMAI was defined as the total number of mitotic figures counted in 10 random fields through the whole outlined tumour at 4009 magnification. A correction for the volume percentage of epithelium assessed with stereology yielded the M/V Index and the rM/V Index, respectively. The results of all four methods showed moderate to high correlations. Univariate survival analysis (Kaplan-Meier curves; Mantel-Cox test) confirmed that all four methods had a strong prognostic value (P \ 0.001). The MAI, however, produced the best results. Multivariate analysis showed that all four methods had additional prognostic value to tumour size and lymph node status. The M/V Index provided most additional prognostic information, followed by the MAI. Assessment of rMAI took 20-30 min on average, about two times longer than MAI. The correction for volume percentage of epithelium for both methods took about 10 min longer than the uncorrected methods. In conclusion, the rMAI gives an impression of the mitotic activity through the whole tumour, with almost similar prognostic value as the traditional MAI, especially when correcting for percentage of epithelium. Nevertheless, the MAI is still to be preferred, because the assessment is easy to apply and less time consuming.
Immunohistochemical alternatives for MAI
In spite of the strong scientific evidence for MAI to prognosticate and predict the outcome of breast cancer patients, mitosis counts are not well liked by many pathologists, particularly due to issues with section quality, time required and difficulties in reliably distinguishing mitoses. Clearly, an accurate immunohistochemical proliferation marker would be very valuable, both for a better understanding of the biology and assessment of proliferating cell fractions in tumours, and an improvement in treatment decisions and prognosis [35] [36] [37] [38] [39] [40] [41] . Unfortunately until recently most available immunohistochemical markers are weaker prognosticators than the MAI [42] . This may be due to the fact that mitotic figures reflect a very small time window in the cell cycle (i.e. the M phase), whereas other markers such as Ki-67 stains cells in nearly all phases of the cell cycle. Many Ki-67-positive nuclei may not survive the cell cycle and are driven into apoptosis, thereby blurring the prognostic value of the Ki-67 index. However, mitoses are very late cell cycle markers, and once formed are reliable proliferative markers. Ideally, any substitute immunohistochemical proliferation marker should be expressed only in late G2 and M phase.
Phosphohistone H3 (PPH3)
Recent studies have demonstrated a tight correlation between phosphorylation of histone 3 (PPH3) and mitotic chromatin condensation; these studies used an antibody selective for the Ser-10 phosphorylated histone H3 (PPH3) amino-terminus [43-46]. PPH3 expression has been characterized in human endometrium, colorectal cancers, ovarian serous adenocarcinomas, and meningiomas. In one small study of breast cancers, PPH3 expression was much less frequent than Ki-67 expression, and there was a strong correlation between PPH3 expression and mitotic counts, suggesting that PPH3 counts can be used for grading of breast adenocarcinomas [46] . Indeed, in a subsequent study on CMF-treated node negative breast cancers, strong phosphohistone H3 expression occurred preferentially in the peripheral growing front. The stain was stable, contrastrich and crisp (Fig. 6a) ; counts were highly reproducible between observers and highly consistent with digital image analysis. Phosphohistone H3 values correlated with tumour diameter, estrogen receptor, carcinoma grade, MAI and were systematically (80%) higher than the MAI. Receiver operating curve analysis and subgroup analysis using median, tertiles, quartiles and pentiles objectively showed that PPH3 \ 13 (45% of all cases) versus phosphohistone H3 C 13 (55% of all cases) was the strongest prognostic threshold, with a 20-year recurrence-free survival of distant metastases of 96% and 58%, respectively (P = 0.0002, HR = 9.6). Mitotic activity index was the second strongest prognostic variable (P = 0.003, HR = 3.9). In multivariate analysis, phosphohistone H3 \13 versus C13 exceeded the prognostic value of the MAI (Fig. 6) [43] . None of the other classical prognostic factors examined offered prognostic value additional to phosphohistone H3. The PPH3 is by far the strongest prognostic variable in early invasive node-negative breast cancer patients less than 55 years old with long-term follow-up. Independent validation has confirmed these promising data [47] .
Cyclin A, B and E Cyclins are another promising immunohistochemical alternative. The stains can be contrast-rich, crisp and therefore well reproducible. In one pT 1 /pT 2 N 0 study, the significance of cyclins A, B and E varied and was menopausal status dependent [48] . In postmenopausal women, disease specific survival was significantly predicted by cyclin E, but in premenopausal patients by cyclin B. No statistical significance was found for cyclin A. With multivariate analysis, cyclin E lost its significance, whereas cyclin B remained the only independent prognostic factor, making it especially promising [49, 50] . However, the biological significance of isolated cytoplasmic expression of cyclin B remains unclear [37, 49] and further studies are needed to validate its prognostic value in node negative breast cancer.
Geminin
The Geminin protein is expressed during S-G2-early M phases to ensure the genomic stability of the cell. Immunohistochemical expression of Geminin identifies which cells have already entered S-phase and proceed to the mitosis. The number of cells stained with Geminin antibody is lower than cells stained with antibodies against Ki-67 protein, correlates with clinical-pathological parameters [51] and correlates with poor overall prognosis in one study [52] but not in another [39] . Other molecular markers mRNA expression levels of E2F1 (a key transcription factor involved in proliferation, differentiation and apoptosis) outcome was comparably predictable by E2F1 levels, by the 70-gene signature, by the intrinsic subtype gene classification, by the wound response signature and by the recurrence score [54] . Validation of these E2F1 results must still be done in independent studies, but it is interesting that the survival results are comparable with those of prognostic gene signatures and the MAI studies, strengthening the key role of proliferation in prognostication.
The serine protease urokinase-type plasminogen activator uPA, in concert with its inhibitor plasminogen activator inhibitor (PAI-1), promotes tumour cell adhesion, migration, and proliferation, as well as extracellular matrix degradation and, thus, facilitates tumour cell invasion and metastasis. Combined uPA/PAI-1 over-expression, as determined by a highly validated and accurate ELISA test, appears to be strongly prognostic [55, 56] . However, with longer follow-up, the initial differences between positive and negative patients may decrease, although a small study with ten years' follow-up suggested otherwise [57] Regardless, with decreasing size of primary tumours due to wide-spread screening [58] , the ELISA assay for uPA/PAI-1, which requires 4,300 mg fresh/frozen tissue (comparable with 1.5 9 1.5 9 1.5 cm cancer tissue) may logistically not be practical. Although a micro-ELISA has been developed for smaller specimens, such as core needle biopsies, the prognostic utility of this assay has not been validated. Unfortunately, immunohistochemical assays of the uPA/PAI-1 system have provided unsatisfactory results [59] . Another small uPA/PAI-1 mRNA expression [60] study showed that the level of PAI-1 mRNA rather than uPA gene expression appeared to be the strongest prognostic factor for survival, although another larger study (317 patients) showed the opposite [61] . These discrepancies show that more validation studies are necessary before uPA/PAI-1 can be used in the clinic to separate lowfrom high-risk breast cancer patients.
MAI/proliferation, basal cell type and triple negative cancers
Recent gene expression studies have shown that breast cancers can be classified into five main groups with prognostic and predictive value: luminal A and B, normal breast like, HER2 positive, and basal-cell like [62, 63] . Many investigators have used the surrogate immunohistochemical markers to classify these tumours. ER, PR, and HER2 negative breast cancers (Triple Negative breast cancer Profile = TNP) are classified as normal breast like if basal cytokeratins and EGFR are lacking, and basal-cell like cancers = BLC when basal cytokeratin (CK5-6 and/or CK14) are expressed. Most breast cancer studies contain 8-15% TNPs and 10-15% BLCs and mortality in these cancers is high (30-50% in lymph node negative breast cancers). It has been shown that TNP and basal like breast cancers are often (but not always) associated with high proliferation, high grade, young age, BRCA1 and aggressive clinical behaviour. A recent comparison of several prognostic gene signatures in breast cancer found that most models had high rates of concordance in their outcome predictions for the individual samples [64] . In particular, almost all tumours identified as having an intrinsic subtype of basal-cell like, HER2-positive and estrogen-receptornegative, or luminal B (associated with a poor prognosis) were also classified as having a poor 70-gene profile, activated wound response, and high recurrence score. However, as far as is known, a formal comparison between the TNPs, basal cell type and proliferation, and the additional or independent prognostic value remains to be done.
MAI and apoptosis
Apoptosis plays an important role in carcinogenesis and tumour growth is determined by the rate of cell proliferation and cell death. Induction of apoptosis by chemotherapeutics is one of the key factors in cancer therapy. Apoptosis is regulated positively and negatively by a wide range of gene products like bcl-2, bcl-x, bcl-x L , bcl-x S [65] [66] [67] , Bak and Bax. The balance between these proteins, by forming bax/ bax, bax/bcl-2 or bax/bcl-x L homo-and heterodimers, can be regulated by several factors, including p53 and c-myc, which may render the cells more susceptible to apoptosis by lowering the bcl-2/bax ratio [68] . Bcl-2, bcl-x, bak and bax are expressed in normal breast glandular epithelium and in a subset of breast carcinomas [69] [70] [71] [72] [73] [74] [75] [76] . The resistance of cells to undergo apoptosis is in part regulated by the above described gene products. The number of apoptotic cells and the expression of bcl-2 have found to be related in invasive breast cancer [77] . The rate of apoptotic cells in a tumour correlates to the MAI and shorter overall survival in lymph node positive but not in node negative patients. However, the MAI is the dominant prognostic factor in multivariate analysis [78] .
MAI, vascularisation and lymph vessel invasion
Many studies have evaluated the prognostic value of microvessel quantification in invasive breast cancer and the majority have found that a high number of microvessels are associated with a shorter survival [79] , though exceptions could be caused by several methodological aspects [80, 81] . Hot-spot microvessel density counts (HS-MVD) in a limited number of fields of vision together with the MAI strongly predicted outcome [82] . Vascular endothelial growth factors (VEGF) could modulate vessel density and in cancers of the bladder and endometrium, the Proliferative Vascular Index indeed had much stronger prognostic value than MVD [83, 84] . The prognostic value of the PVI in breast cancer is not yet known.
Another historical prognostic vessel marker (especially in node-negative patients) is lymph vessel invasion (LVI), which was recently incorporated into the St. Gallen international consensus criteria for selection of adjuvant systemic treatment in operable breast cancer [85] . Unfortunately, LVI is not well reproducible in standard haematoxylin-eosin stained sections. D2-40 is a specific immunohistochemical stain for lymph vessels, correlates with Ki-67 and in one study was an overall strong prognosticator [86] . Analysis of D2-40 by Tissue Micro Array = TMA is risky, as TMA technology does not always cope with tumour heterogeneity [87] ; D2-40 lymph vessels can occur very focally and thereby be easily missed in TMAs, small as those samples are. This would be especially important in studies with relatively small numbers of patients analyzed (\200) in which the statistical basis of TMA (''Do more less well'') may not be fulfilled. Moreover, myoepithelial markers are important in conjunction with D2-40 to distinguish solid intralymphatic tumour emboli from solid pattern in situ carcinoma [88] . An independent prognostic comparison of D2-40 expression to the MAI and other proliferation markers also remains to be assessed.
MAI and CGH
Alterations in the genetic make-up of tumour cells are at the basis of the phenotypical characteristics and the biological behaviour of a tumour. A considerable amount of chromosomal and molecular data on breast cancer is available [89] but most studies have either used mixtures of node negative and positive cancers, had small patient numbers or lacked adequate follow-up. As a result, little is known of lymph node-negative breast cancer; of the relationship between specific chromosomal gains and losses, clinical behaviour and outcome [90] . Comparative Genomic Hybridization allows the detection of chromosomal gains and losses throughout the whole genome in a single experiment [91] but the resolution of classical chromosome CGH (10-20 Mb) is a limiting factor. Resolution of array-CGH is much better (\100 Kb) and chromosomal aberrations have been linked to grade, oestrogen receptor status, TP53 mutation, gene expression sub-type and overall survival. None of the studies have compared MAI/ proliferation with array-CGH profiling. With classical CGH, amplification of 3q26 was a much better prognosticator than MAI, but these data still have to be validated [92] .
Proliferation and gene signatures
High-throughput genomic technologies have been used to predict response to therapy, characterize normal breast cells, perform genomic histological grading and staging [63, 93] , and identify patient characteristics that may influence tumour behaviour [94] [95] [96] , amongst others. Much attention has been drawn to gene signatures because of the impressive prognostic value in node-negative breast cancer patients in one study [96] with a HR of around 5, stronger than any classical feature in node-negative breast cancer patients without systemic adjuvant chemotherapy [97] . However, subsequent studies had less impressive results [98] [99] [100] . Although the 70-gene profile signature was again prognostic, outperforming classic prognostic criteria such as those used by the St. Gallen consensus panel, the magnitude of prognostic effect was much less than what was reported in the first publication [96] , with HRs of 1.9-2.5. In comparison, in a recent large multicentre prospective validation analysis the HRs for the MAI were 3.1-4.4.
Unfortunately, not the MAI but grade (which is much less prognostic on node negative cancer) has been evaluated in the gene signature studies, but the following comparison still can be made on the basis of the current data. Prognostic gene signatures for node negative breast cancers classify nearly two thirds of these patients as unfavourable but only 15-30% of all node-negative patients develop distant metastases. Consequently, selection of T 1-2 N 0 M 0 invasive breast cancer patients for adjuvant therapy by the 70-gene signature means serious overtreatment. Moreover, the survival curves of gene signatures in recent validation studies are very similar to the ones found for the MAI and also PPH3 [43, 47] . As only thirty to forty percent of the T 1-2 N 0 M 0 patients are prognostically unfavourable according to MAI and PPH3, the number of over-treated patients is much lower when proliferation features are used as the primary prognostic classifier, rather than is the case with gene signatures.
Proteomics
The first evidence that SELDI-TOF MS serum protein profiling can provide prognostic information in early breast cancer [101] used a 40-protein index identifying two classes of patients with 83% and 22% survival and the strongest independent prognosticator in multivariate analysis. Another study found that two protein peaks (ubiquitin and ferritin light chain) were strongly prognostic [102] . However, relatively small numbers were analyzed and the results must be validated and refined. For application in routine diagnostics, multivariate immunohistochemical protein analysis (= IHC) may be an important alternative for SeldiTof or MS/MS proteomics analysis [103] , but for standardization purposes IHC should be automated and expression be done by automated quantitative image analysis using adequate calibration methods.
Conclusions
Accurate assessment of the MAI under a strict quality control protocol is still, to date, the strongest, most well reproducible prognosticator and chemotherapy success predictor available. PPH3 counts are prognostically stronger than the MAI, and markers such as cyclin-B and E2FR are promising, but must be validated. Compared with commercial prognostic gene expression signatures, the MAI is at least as strong prognostically, has far fewer false positive results and as such should be included as an independent feature in any node negative breast cancer pathology report. 
